New cancer drug enters first human safety trial
NCT ID NCT06001580
Summary
This was a very early, small study to test the safety of a new drug called BR101 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose for future studies by giving the drug to 15 participants and closely monitoring them for side effects. Researchers also collected initial information on how the drug behaves in the body and whether it showed any signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Zhejiang University Medical College
Hangzhou, Zhejiang, 310052, China
Conditions
Explore the condition pages connected to this study.